Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1673 - The prognostic value of different molecular subtypes of breast cancer in relation to Enhancer-of-zeste homologue 2 expression

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Zohreh Sanaat

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

Z. Sanaat, R. Dolatkhah

Author affiliations

  • Hematology And Oncology Research Center,tabriz University Of Medical Science,tabriz,iran, Hematology and Oncology Research Center,Tabriz University Of Medical Science,Tabriz,Iran, 51656 - Tabriz/IR
More

Resources

Abstract 1673

Background

Studies have shown that Enhancer-of-zeste homologue 2 (EZH2) plays an important role in carcinogenesis in the breast cancer, and invasion and progression of the disease. We aimed to assess the prognostic value of different molecular subtypes of breast cancer in relation to EZH2 expression.

Methods

We performed a cross-sectional analytical research study on 100 breast cancer women. Survival analysis was then performed using the Kaplan–Meier method, with log-rank tests to assess statistical significance between groups. To assess the effects of variables on OS and DFS, a Cox proportional-hazard model was then used to give adjusted hazard ratios (HRs) with 95% confidence intervals (CIs).

Results

Samples were collected for 100 women with breast cancers, with follow-up data collected over a 5-year period. The mean age was 51.5 ± 9.54 years (range, 34–75 years), By molecular subgroup, 43% had luminal A tumors, 41% had luminal B tumors, 9% had HER2 tumors, and 7% had TNBC tumors. Overall, 74% had high EZH2 expression, which was most common for the luminal A subtype (43.2%) and least common for the TNBC subtype (8.1%). There was no significant correlation between subgroups by EZH2 expression (P = 0.33).

Conclusions

In conclusion, although our results provide some interesting insights, there remains controversy about the prognostic value of different molecular subtypes of breast cancer in relation to EZH2 expression. Given that there are very few studies on this topic, we advocate further research with larger sample sizes and the inclusion of molecular techniques.

Clinical trial identification

This study was conducted as part of a fellowship thesis for Dr Boostani (thesis no 94/5-9/30). Dr Robert Sykes (www.doctored.org.uk) provided technical editing services for the final drafts of this manuscript.

Legal entity responsible for the study

The study protocol was approved by the ethics committee of Tabriz University (permit no. 5/d/988072).

Funding

Hematology and Oncology Research Center, Tabriz University of Medical Science, Tabriz, Iran.

Editorial Acknowledgement

This study was conducted as part of a fellowship thesis for Dr Boostani (thesis no 94/5-9/30). Dr Robert Sykes (www.doctored.org.uk) provided technical editing services for the final drafts of this manuscript.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings